## Rubi K Li

## List of Publications by Year

 in descending orderSource: https:/|exaly.com/author-pdf/3662643/publications.pdf
Version: 2024-02-01


CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial. Lancet Oncology, The, 2017, 18, 917-928.

PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus

Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast
4 cancer: final results from a randomized phase III trial. Breast Cancer Research and Treatment, 2021,

## 188, 631-640.

Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients
5 with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study.

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced

